U.S. Embassy in Tanzania


Tanzania accepted delivery of over 1.6 million Pfizer BioNTech vaccines donated by the government of the United States through the global COVAX vaccine sharing initiative. Dar es Salaam Regional Medical Officer Dr. Rashid Mfaume officially received the donation from U.S. Agency for International Development (USAID) Health Office Director Ananthy Thambinayagam during a ceremony at Julius Nyerere International Airport.

As part of its efforts to end the pandemic globally, the U.S. government has so far donated over 4.5 million COVID-19 vaccine doses to Tanzania. This total includes more than 1 million doses of the Johnson and Johnson vaccine that were shipped in July 2021 and over 3.5 million doses of the Pfizer BioNTech vaccine that were to shipped in three installments between November 2021 and January 2022. These donations are indicative of the U.S. government’s strong partnership and commitment to the Tanzanian people and our shared interest in defeating COVID-19 together.

America’s support for the global fight against COVID-19 includes:

  • Donating 365 million vaccine doses to other countries.
  • Purchasing 1 billion vaccine doses to donate to nearly 100 developing countries.
  • Contributing $4 billion to Gavi, the Vaccine Alliance, in support of COVAX, the global initiative to equitably distribute safe and effective COVID-19 vaccines worldwide.
  • Delivering essential medicines, supplies and therapeutics, as well as other assistance to help countries rebuild economies, overcome food shortages, and strengthen health security.

U.S. President Joe Biden has pledged that the United States will be the world’s arsenal of vaccines in the shared fight against COVID-19. “We will continue to do all we can to build a world that is safer and more secure against the threat of infectious disease,” Biden said earlier this year.

Distributed by APO Group on behalf of U.S. Embassy in Tanzania.

Send us your press releases to pressrelease.zawya@refinitiv.com


© Press Release 2021

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.